Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patie...
Gespeichert in:
Veröffentlicht in: | Neurobiology of aging 2011-12, Vol.32 (12), p.2320.e15-2320.e32 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2320.e32 |
---|---|
container_issue | 12 |
container_start_page | 2320.e15 |
container_title | Neurobiology of aging |
container_volume | 32 |
creator | Darreh-Shori, Taher Forsberg, Anton Modiri, Negar Andreasen, Niels Blennow, Kaj Kamil, Chelenk Ahmed, Hiba Almkvist, Ove Långström, Bengt Nordberg, Agneta |
description | Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau ( r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells. |
doi_str_mv | 10.1016/j.neurobiolaging.2010.04.028 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_550841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458010002034</els_id><sourcerecordid>911157939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7jj6FyQXwl5ox5P0IymIMOyHCgte-HEb0va0k9lOUpN2hvG_-F9Nd8YFBR0hkEPy5D0teRJFLygsKND89XphcHS21LZTrTbtgkHYgnQBTDyIZjTLREzTgj-MZkALHqeZgLPoifdrAOApzx9HZwyyRCQ8nUU_LnXToEMzaNWRDrfYeWIbonrb6d72zg6oDbkiytSkHIe923fVKuwZ9AM65ZH4ld0RPzhrWqK8t5VWg7aG7PSwIr0aAm1bXYV4r1tzl77svq9Qb9Cde1Jrj1NM6DKskJROhSqMrd7ap9GjRnUenx3nefTl-urzxfv45uO7DxfLm7jKs2SIEwE0FU2NNaW8ZFiWTV1XAA0IEE1RIeeqSKApacNYVpahVgwQa84K2uRFMo_iQ67fYT-Wsnd6o9xeWqXlcek2VCizDERK_8m3Yy_DUjtOPGW5oCLwr_7KX-qvS2ldK8dR0pyld_EvT-N-lBzSNAv0-YEOl_VtDNciN9pX2HXKoB29LCilGS-S4jQJLMk5z_KTpCgELSgEfh69OZCVs947bO6_loKchJVr-buwchJWQiqDsOH482OjsdxgfX_4l6EBuD4AQUzcanTSVxpNhbV2WA2ytvp_O739I6gKFk9e3uIe_dqOzgTHJJWeSZCfpsczvZ3wl8AgSZOf14gfkQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898191002</pqid></control><display><type>article</type><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</creator><creatorcontrib>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</creatorcontrib><description>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau ( r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</description><identifier>ISSN: 0197-4580</identifier><identifier>ISSN: 1558-1497</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2010.04.028</identifier><identifier>PMID: 20538374</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Alzheimer Disease - cerebrospinal fluid ; Alzheimer Disease - enzymology ; Alzheimer Disease - pathology ; Alzheimer’s disease ; apolipoprotein E ; Apolipoprotein E4 - blood ; Apolipoprotein E4 - cerebrospinal fluid ; Biomarkers - blood ; Biomarkers - cerebrospinal fluid ; brain ; Brain - enzymology ; Brain - pathology ; butyrylcholinesterase ; Butyrylcholinesterase - cerebrospinal fluid ; Female ; Humans ; Internal Medicine ; Male ; Middle Aged ; Neurology ; Psychiatry ; Psychology ; Psykiatri ; Psykologi ; Risk Factors ; SAMHÄLLSVETENSKAP ; SOCIAL SCIENCES ; Socialvetenskap</subject><ispartof>Neurobiology of aging, 2011-12, Vol.32 (12), p.2320.e15-2320.e32</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</citedby><cites>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0197458010002034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20538374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-70445$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-162441$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/126818$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:123531267$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Darreh-Shori, Taher</creatorcontrib><creatorcontrib>Forsberg, Anton</creatorcontrib><creatorcontrib>Modiri, Negar</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Kamil, Chelenk</creatorcontrib><creatorcontrib>Ahmed, Hiba</creatorcontrib><creatorcontrib>Almkvist, Ove</creatorcontrib><creatorcontrib>Långström, Bengt</creatorcontrib><creatorcontrib>Nordberg, Agneta</creatorcontrib><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau ( r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</description><subject>Aged</subject><subject>Alzheimer Disease - cerebrospinal fluid</subject><subject>Alzheimer Disease - enzymology</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer’s disease</subject><subject>apolipoprotein E</subject><subject>Apolipoprotein E4 - blood</subject><subject>Apolipoprotein E4 - cerebrospinal fluid</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>brain</subject><subject>Brain - enzymology</subject><subject>Brain - pathology</subject><subject>butyrylcholinesterase</subject><subject>Butyrylcholinesterase - cerebrospinal fluid</subject><subject>Female</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psykiatri</subject><subject>Psykologi</subject><subject>Risk Factors</subject><subject>SAMHÄLLSVETENSKAP</subject><subject>SOCIAL SCIENCES</subject><subject>Socialvetenskap</subject><issn>0197-4580</issn><issn>1558-1497</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNk12L1DAUhoso7jj6FyQXwl5ox5P0IymIMOyHCgte-HEb0va0k9lOUpN2hvG_-F9Nd8YFBR0hkEPy5D0teRJFLygsKND89XphcHS21LZTrTbtgkHYgnQBTDyIZjTLREzTgj-MZkALHqeZgLPoifdrAOApzx9HZwyyRCQ8nUU_LnXToEMzaNWRDrfYeWIbonrb6d72zg6oDbkiytSkHIe923fVKuwZ9AM65ZH4ld0RPzhrWqK8t5VWg7aG7PSwIr0aAm1bXYV4r1tzl77svq9Qb9Cde1Jrj1NM6DKskJROhSqMrd7ap9GjRnUenx3nefTl-urzxfv45uO7DxfLm7jKs2SIEwE0FU2NNaW8ZFiWTV1XAA0IEE1RIeeqSKApacNYVpahVgwQa84K2uRFMo_iQ67fYT-Wsnd6o9xeWqXlcek2VCizDERK_8m3Yy_DUjtOPGW5oCLwr_7KX-qvS2ldK8dR0pyld_EvT-N-lBzSNAv0-YEOl_VtDNciN9pX2HXKoB29LCilGS-S4jQJLMk5z_KTpCgELSgEfh69OZCVs947bO6_loKchJVr-buwchJWQiqDsOH482OjsdxgfX_4l6EBuD4AQUzcanTSVxpNhbV2WA2ytvp_O739I6gKFk9e3uIe_dqOzgTHJJWeSZCfpsczvZ3wl8AgSZOf14gfkQ</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Darreh-Shori, Taher</creator><creator>Forsberg, Anton</creator><creator>Modiri, Negar</creator><creator>Andreasen, Niels</creator><creator>Blennow, Kaj</creator><creator>Kamil, Chelenk</creator><creator>Ahmed, Hiba</creator><creator>Almkvist, Ove</creator><creator>Långström, Bengt</creator><creator>Nordberg, Agneta</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG7</scope><scope>DF2</scope><scope>F1U</scope></search><sort><creationdate>20111201</creationdate><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><author>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Alzheimer Disease - cerebrospinal fluid</topic><topic>Alzheimer Disease - enzymology</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer’s disease</topic><topic>apolipoprotein E</topic><topic>Apolipoprotein E4 - blood</topic><topic>Apolipoprotein E4 - cerebrospinal fluid</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>brain</topic><topic>Brain - enzymology</topic><topic>Brain - pathology</topic><topic>butyrylcholinesterase</topic><topic>Butyrylcholinesterase - cerebrospinal fluid</topic><topic>Female</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psykiatri</topic><topic>Psykologi</topic><topic>Risk Factors</topic><topic>SAMHÄLLSVETENSKAP</topic><topic>SOCIAL SCIENCES</topic><topic>Socialvetenskap</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darreh-Shori, Taher</creatorcontrib><creatorcontrib>Forsberg, Anton</creatorcontrib><creatorcontrib>Modiri, Negar</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Kamil, Chelenk</creatorcontrib><creatorcontrib>Ahmed, Hiba</creatorcontrib><creatorcontrib>Almkvist, Ove</creatorcontrib><creatorcontrib>Långström, Bengt</creatorcontrib><creatorcontrib>Nordberg, Agneta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Stockholms universitet</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darreh-Shori, Taher</au><au>Forsberg, Anton</au><au>Modiri, Negar</au><au>Andreasen, Niels</au><au>Blennow, Kaj</au><au>Kamil, Chelenk</au><au>Ahmed, Hiba</au><au>Almkvist, Ove</au><au>Långström, Bengt</au><au>Nordberg, Agneta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>32</volume><issue>12</issue><spage>2320.e15</spage><epage>2320.e32</epage><pages>2320.e15-2320.e32</pages><issn>0197-4580</issn><issn>1558-1497</issn><eissn>1558-1497</eissn><abstract>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau ( r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20538374</pmid><doi>10.1016/j.neurobiolaging.2010.04.028</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0197-4580 |
ispartof | Neurobiology of aging, 2011-12, Vol.32 (12), p.2320.e15-2320.e32 |
issn | 0197-4580 1558-1497 1558-1497 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_550841 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Aged Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - enzymology Alzheimer Disease - pathology Alzheimer’s disease apolipoprotein E Apolipoprotein E4 - blood Apolipoprotein E4 - cerebrospinal fluid Biomarkers - blood Biomarkers - cerebrospinal fluid brain Brain - enzymology Brain - pathology butyrylcholinesterase Butyrylcholinesterase - cerebrospinal fluid Female Humans Internal Medicine Male Middle Aged Neurology Psychiatry Psychology Psykiatri Psykologi Risk Factors SAMHÄLLSVETENSKAP SOCIAL SCIENCES Socialvetenskap |
title | Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20levels%20of%20apolipoprotein%20E%20and%20butyrylcholinesterase%20show%20strong%20association%20with%20pathological%20signs%20of%20Alzheimer's%20disease%20in%20the%20brain%20in%20vivo&rft.jtitle=Neurobiology%20of%20aging&rft.au=Darreh-Shori,%20Taher&rft.date=2011-12-01&rft.volume=32&rft.issue=12&rft.spage=2320.e15&rft.epage=2320.e32&rft.pages=2320.e15-2320.e32&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2010.04.028&rft_dat=%3Cproquest_swepu%3E911157939%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=898191002&rft_id=info:pmid/20538374&rft_els_id=S0197458010002034&rfr_iscdi=true |